-
Article
Open AccessHormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial
Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface prot...
-
Article
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy
SLCO-encoded transporters have been associated with progression to castration-resistant prostate cancer (CRPC) after initiation of androgen deprivation therapy (ADT). Although expressed at lower levels than in CR...
-
Chapter
Canonical and Noncanonical Androgen Metabolism and Activity
Androgens are critical drivers of prostate cancer. In this chapter we first discuss the canonical pathways of androgen metabolism and their alterations in prostate cancer progression, including the classical, ...
-
Article
Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade
Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT)...
-
Article
Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
Some, but not all, epidemiologic evidence supports a role for cholesterol, the precursor for steroid hormone synthesis, in prostate cancer. Using a PTEN-null transgenic mouse model of prostate cancer, we teste...
-
Article
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
Docetaxel plus androgen deprivation therapy (ADT) offers a survival benefit in metastatic hormone-sensitive prostate cancer (mHSPC). However, one trial evaluating docetaxel in mHSPC (GETUG-AFU15) showed unexpe...
-
Article
Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression
Androgens play an important role in prostate cancer (PCa) development and progression. Accordingly, androgen deprivation therapy remains the front-line treatment for locally recurrent or advanced PCa, but pati...
-
Article
Testosterone Regulates Tight Junction Proteins and Influences Prostatic Autoimmune Responses
Testosterone and inflammation have been linked to the development of common age-associated diseases affecting the prostate gland including prostate cancer, prostatitis, and benign prostatic hypertrophy. We hyp...
-
Article
Erratum: Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
Nature Clinical Practice Urology (2009) 6: 76–85 [doi:10.1038/ncpuro1296] In the Review by Harris et al. published in the February 2009 issue of Nature Clinical Practice Urology, the competing interests inform...
-
Article
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
In this Review, Harris and colleagues discuss historical and contemporary approaches to androgen deprivation therapy for patients with prostate cancer. They then focus on mechanisms of castration resistance, a...
-
Article
The basic biochemistry and molecular events of hormone therapy
Data regarding the molecular response of prostate cancer to hormone therapy continue to emerge, identifying a complex network of autocrine and paracrine signaling events mediating the tumor response to androge...
